Associated Papers
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
39774325 (PubMed )
Supplement: 41588_2024_2039_MOESM5_ESM.xlsx › SuppFig6
Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.
Banerjee S et al.
Cancers, 2021
34068918 (PubMed )
Supplement: cancers-13-02366-s001.zip › Supplementary_Tables_1202501.xlsx › Table_S7
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.
Bauer MR et al.
Acs Chemical Biology, 2020
Oncogene-mediated regulation of p53 ISGylation and functions.
Huang YF et al.
Oncotarget, 2014
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Sutherland HS et al.
Investigational New Drugs, 2012
The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells.
Hwang IY et al.
Cancer Letters, 2010
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
19005564 (PubMed )
Supplement: pone.0003714.s004.xls › Table_s-2
Select a paper to view details